Mineralys Therapeutics, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Mineralys Therapeutics hired James J. Ferguson III as Chief Medical Officer effective August 10, 2026. Ferguson receives a $550,000 annual base salary, 50% target bonus, 135,000 stock options, and 102,400 RSUs vesting over 4 years. In a qualifying termination, he is entitled to 9 months severance (or 12 months if within 12 months of a change-in-control), prorated bonus, and accelerated vesting of service-based equity.
Why this rating
C-suite hire is routine for ongoing operations. Equity grant (~$4–8M at typical biotech valuations) is material in aggregate but standard for CMO role. No strategic deal, financial restatement, or business disruption disclosed.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.